Free shipping on all orders over $ 500

Vilobelimab

Cat. No. M25043
Vilobelimab Structure
Synonym:

CaCP-29, IFX-1

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc.

Chemical Information
CAS Number 2250440-41-4
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Matthew W McCarthy. Expert Opin Biol Ther. Optimizing the use of vilobelimab for the treatment of COVID-19

[2] No authors listed. Vilobelimab

[3] Alexander P J Vlaar, et al. Lancet Respir Med. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

[4] Haruki Koike, et al. Neurol Ther. ANCA-Associated Vasculitic Neuropathies: A Review

[5] Alexander P J Vlaar, et al. Clin Transl Sci. The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19

Related Complement System Products
P014

P014 is a C5 antibody/CFH fragment fusion protein that can be used in studies related to paroxysmal sleep hemoglobinuria (PNH) and thrombotic microangiopathy (TMA).

POT-4

POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation.

TLQP-21

TLQP-21, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor 1 (C3aR1) agonist (EC50: mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM).

N-((Allyloxy)carbonyl)-N-methyl-L-alanine

N-((Allyloxy)carbonyl)-N-methyl-L-alanine is a Alanine derivative.

C5a Receptor agonist, mouse, human

C5a Receptor agonist, mouse, human is a biological active peptide.

  Catalog
Abmole Inhibitor Catalog




Keywords: Vilobelimab, CaCP-29, IFX-1 supplier, Complement System, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.